The Effect of Rational Iron Medication Use on Pregnancy Hemogram

Öz

Objective: This study aims to determine the rational use of oral iron drugs during pregnancy and the factors affecting the hemogram level. Material and Method: The research was conducted at a hospital in Istanbul, Turkey between February 15 and 30 September 2019. This descriptive study was carried out with the participation of 303 low-risk pregnant women. All participants received oral iron supplements during pregnancy. The data were collected using the participant information form and Rational Medicine Use Scale. Results: The mean age of the pregnant women was 30.58±5.63 years. 37.6% of the participants were found to have haemoglobin levels below 11g/dl before pregnancy, 19.5% in their first trimester, and 32.3% in their third trimester. A significant relationship was found between the first-trimester anemia status and the third-trimester haemoglobin and haematocrit levels (p=0.000). A significant relationship was observed between third-trimester haemoglobin and haematocrit values and regular use of oral iron medication, and compliance of fetus to gestational week (p=0.003; p=0.001). A significant relationship was detected between the education level of pregnant women, income status perception and the Rational Medicine Use Scale mean scores (p=0.000; p=0.028). Conclusion: Regular use of oral iron medication during pregnancy has affected third-trimester haemoglobin and haematocrit levels and fetal development positively. Nurses and midwives should explain and emphasize the importance of the correct-rational use of iron drugs for pregnant women.

Anahtar Kelimeler

• Anemia
• haemoglobin
• iron-deficiency anemia
• pregnancy.

Oral Demir İlacının Akılcı Kullanımının Gebelikte Hemogram Düzeyine Etkisi

Öz

Amaç: Bu çalışmada gebelikte oral demir ilaçlarının akılcı kullanımı ve hemogram düzeyini etkileyen faktörlerin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Araştırma, Türkiye’nin İstanbul ilinde bulunan bir hastanede 15 Şubat-30 Eylül 2019 tarihleri arasında yapılmıştır. Tanımlayıcı tipteki bu çalışma 303 düşük riskli gebenin katılımıyla gerçekleştirilmiştir. Tüm katılımcılar gebelik sırasında oral demir takviyesi almıştır. Veriler “Katılımcı Bilgi Formu” ve “Akılcı İlaç Kullanım Ölçeği” kullanılarak toplanmıştır. Bulgular: Gebelerin yaş ortalaması 30,58±5,63 yıl idi. Katılımcıların %37,6’sının gebelik öncesi, %19,5’inin ilk trimesterde ve %32,3’ünün üçüncü trimesterde hemoglobin düzeylerinin 11g/dl’nin altında olduğu tespit edilmiştir. Birinci trimester anemi durumu ile üçüncü trimester hemoglobin ve hematokrit düzeyleri arasında anlamlı ilişki bulunmuştur (p=0,000). Üçüncü trimester hemoglobin ve hematokrit değerlerine göre oral demir ilacının düzenli kullanımı ile fetüsün gebelik haftası ile uyumu arasında anlamlı ilişki gözlenmiştir (p=0,003; p=0,001). Gebelerin eğitim düzeyi, gelir durumu algısı ile Akılcı İlaç Kullanım Ölçeği puan ortalamaları arasında anlamlı ilişki saptanmıştır (p=0.000; p=0.028). Sonuç: Gebelikte düzenli oral demir ilacı kullanımı üçüncü trimester hemoglobin ve hematokrit değerlerini ve fetal gelişimi olumlu yönde etkilemiştir. Gebelere demir ilaçlarının doğru-akılcı kullanımının önemi hemşire ve ebeler tarafından anlatılmalı ve vurgulanmalıdır.

Anahtar Kelimeler

• Anemi
• hemoglobin
• demir eksikliği anemisi
• gebelik.

Kaynakça

1. Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008 Dec;87(12):949-59.
2. Vural T, Özcan A, Sancı M. Current information about iron deficiency anemia in pregnancy: Iron supplementation for whom? When? How much? Van Med J. 2016;23(4):369-76.
3. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva; 2011. Available from: https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_ MNM_11.1_eng.pdf
4. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. Atlanta; 1998. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm
5. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013 Jan 15;87(2):98-104.
6. World Health Organization/Centers for Disease Control and Prevention (WHO/CDCP). Worldwide prevalence of anemia 1993-2005. Geneva;2008 [Updated: 2008; Cited: 2021 Feb 9]. Available from: https://stacks.cdc.gov/view/cdc/5351
7. Halk Sağlığı Genel Müdürlüğü (HSGM). Doğum Öncesi Bakım Yönetim Rehberi. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Ankara; 2018 [Cited: 2021 Feb 9]. https://khgmsaglikhizmetleridb.saglik.gov.tr/Eklenti/28085/0/dogumoncesibakimyönetimrehberipdf.pdf
8. Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J, FER-ASAP investigators. Ferric carboxymaltose vs oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017 May 24;45(4):443-53.

9. Friedrisch JR, Friedrisch BK. Prophylactic Iron Supplementation in Pregnancy: A Controversial Issue. Biochemistry Insights. 2017 Oct 27;27,10:1178626417737738.
10. Schantz-Dunn J, Barbieri RL. Recognize and treat iron deficiency anemia in pregnant women. OBG Manag. 2017 December;29(12):8-11.
11. Sürmelioğlu N, Kıroğlu O, Erdoğdu T, Karataş Y. Akılcı olmayan ilaç kullanımını önlemeye yönelik tedbirler. Arşiv Kaynak Tarama Dergisi. 2015;24(4): 452-462.
12. Kaptanoğlu AY. Sağlık Alanında Hipotezden Teze:Veri Toplama ve Çözümleme Serüveni. 1. Basım, Beşir Kitabevi, İstanbul; 2013, s: 127- 144.
13. The American College of Obstetricians and Gynecologists. Anemia in pregnancy. Obstet Gynecol 2021;138:e55–64.Available from:https:// journals.lww.com/ greenjournal/Fulltext/2021/08000/Anemia_in_ PregnancyACOG_Practice_Bulletin,.34.aspx
14. Demirtaş Z, Dağtekin G, Sağlan R, Alaiye M, Önsüz MF, Işıklı B, et al. Akılcı ilaç kullanımı ölçeği geçerlilik ve güvenilirliği. ESTÜDAM Halk Sağlığı Dergisi. 2018;3(3):37-46.
15. Kayış A. Güvenirlik analizi, Ş. Kalaycı (Ed.) SPSS Uygulamalı Çok Değişkenli İstatistik Teknikleri 2009; s.403-419, 4.Baskı, Ankara: Asil Yayın Dağıtım Ltd. Şti.
16. Kılıç S. Cronbach’s alpha reliability coefficient, Journal of Mood Disorders, 2016; 6 (1): 47-49.
17. Auerbach M, Abernathy J, Juul S, Short V, Derman R. Prevalence of iron deficiency in first trimester, nonanemic pregnant women. J Matern Fetal Neonatal Med. 2021 Mar;34(6):1002-5.
18. Baştürk A, Kutlucan L, Kutlucan A, Pekin AT, Akıncı S, Dağlı M, et al. Evaluation of pregnant women awareness about anemia and factors affecting the development of anemia. Eur J Health Sci. 2016;2(1):1-4.
19. Pulatoğlu Ç, Başbuğ D, Akar B, Şimşek H, Çakır P, Başbuğ A, et al. Maternal and neonatal outcomes related to iron defıcıency anemia and serum ferritin status: a multicenter prospective study from eastern marmara, Turkey. Namık Kemal Tıp Dergisi. 2019;7(3):228-35.
20. Karaoglu L, Pehlivan E, Eğri M, Deprem C, Gunes G, Genc MF, et al. The prevalence of nutritional anemia in pregnancy in an east Anatolian province Turkey. BMC Public Health. 2010;10:329.
21. Kabalcıoğlu Bucak F, Özcanarslan F, Demir M. The prevalence of anemia and related factors in pregnant women admitted to Sanliurfa maternity hospital. Health Care Acad J. 2017 Sep;4(2):103-9.
22. Morasso MC, Molero J, Vinocur P, Acosta L, Paccussi N, Raselli S, et al. Iron deficiency and anemia in pregnant women from Chaco, Argentina. Archivos Latinoamericanos De Nutricion. 2002;52:336-43.
23. Tan J, He G, Qi Y, Yang H, Xiong Y, Liu C, et al. Prevalence of anemia and iron deficiency anemia in Chinese pregnant women (Iron Women): a national cross-sectional survey. BMC Pregnancy Childbirth. 2020;20, 670.
24. Ngimbudzi EB, Massawe SN, Sunguya BF. The Burden of Anemia in Pregnancy Among Women Attending the Antenatal Clinics in Mkuranga District, Tanzania. Front. Public Health. 2021 Dec 2;9:724562.
25. Shams S, Ahmad Z, Wadood A. Prevalence of Iron Deficiency Anemia in Pregnant Women of District Mardan, Pakistan. J Preg Child Health. 2017 Nov 08;4:356.
26. Yıldız Y, Yapar Eyi EG. Maternal anemia in pregnancy. Jinekoloji- Obstetrik ve Neonatoloji Tıp Dergisi. 2012; 9(35):1456-1459.
27. Birhanu TM, Birarra MK, Mekonnen FA. Compliance to iron and folic acid supplementation in pregnancy, Northwest Ethiopia. BMC Res Notes. 2018 May 30;11(1):345.
28. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW, Nutrition Impact Model Study Group. Anemia, prenatal iron use, and risk of adverse pregnancy outcomes:systematic review and meta-analysis. BMJ. 2013 June;346:1-19.
29. Aranda N, Ribot B, Garcia E, Viteri FE, Arija V. Pre-pregnancy iron reserves, iron supplementation during pregnancy, andbirth weight. Early Hum Dev. 2011 Jun; 87(12):791-7.
30. Sloan NL, Jordan E, Winikoff B. Effects of iron supplementation on maternal hematologic status in pregnancy. Am J Public Health. 2002 Feb;92(2):288-93.
31. Harvey T, Zkik A, Auges M, Clavel T. Assessment of iron deficiency and anemia in pregnant women: an observational French study. Womens Health. 2016 Jan;12(1):95-102.
32. Moghaddam Tabrizi F, Barjasteh S. Maternal hemoglobin levels during pregnancy and their association with birth weight of neonates. Iran J Ped Hematol Oncol. 2015 Dec; 5(4):211-7.
33. Ren A, Wang J, Ye RW, Li S, Liu JM, Li Z. Low first-trimester hemoglobin and low birth weight, preterm birth and small for gestational age newborns. Int J Gynaecol Obstet. 2007 Aug;98(2):124-8.
34. Wang L, Mei Z, Li H, Zhang Y, Liu J, Serdula MK. Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial. Br J Nutr. 2016 Feb 28;115(4):644-9.
35. Bencaiova G, Breymann C. Mild anemia and pregnancy outcome in a Swiss collective. J Pregnancy. 2014;2014:307535.
36. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. Obstet Gynecol. 2019 Dec;134(6):1234-44.
37. Nair M, Gireesh S, Yakoob R, Cherian NC. Effect of maternal anemia on birth weight of term babies. Int J Contemp Pediatr. 2018 May;5(3):1019-22.
38. Akıcı A, Mollahaliloğlu S, Özgülcü Ş, Dönertaş B, Alkan A. Birinci basamak sağlık merkezlerine ve devlet hastanelerine başvuran hastaların aldıkları sağlık hizmetinin akılcı ilaç kullanımı açısından değerlendirilmesi. Turkish Family Physician. 2015;6(1):31-9.
39. Şendir M, Çelik Z, Güzel E, Büyükyılmaz F. Aile sağlığı merkezlerine başvuran bireylerde akılcı ilaç kullanım alışkanlıklarının belirlenmesi. TAF Preventive Medicine Bulletin. 2015;14(1):15-22.
40. Ekenler Ş, Koçoğlu D. Bireylerin akılcı ilaç kullanımıyla ilgili bilgi ve uygulamaları. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi. 2016;3(3):44-55.
41. Birhanu TM, Birarra MK, Mekonnen FA. Compliance to iron and folic acid supplementation in pregnancy, Northwest Ethiopia. BMC Research Notes. 2018; 11(1):1-5.
42. Demis A, Geda B, Alemayehu T, Abebe H. Iron and folic acid supplementation adherence among pregnant women attending antenatal care in North Wollo Zone northern Ethiopia: institution based cross-sectional study. BMC Research Notes. 2019; 12(1):107.
43. Ugwu EO, Olibe AO, Obi SN, Ugwu AO. Determinants of compliance to iron supplementation among pregnant women in Enugu, Southeastern Nigeria. Niger J Clin Pract. 2014;17(5):608-12.
44. Wiradnyani LAA, Khusun H, Achadi EL, Ocviyanti D, Shankar A. Role of family support and women’s knowledge on pregnancy-related risks in adherence to maternal iron–folic acid supplementation in Indonesia. Public Health Nutrition. 2016;19(15): 2818-2828.
45. Desta M, Kassie B, Chanie H, Mulugeta H, Yirga T, Temesgen H, et al. Adherence of iron and folic acid supplementation and determinants among pregnant women in Ethiopia: a systematic review and meta-analysis. Reprod Health. 2019;16(1):1-14.
46. Bian C, Xu S, Wang H, Li N, Wu J, Zhao Y, et al. A Study on the application of the information-motivation-behavioral skills (IMB) model on rational drug use behavior among second-level hospital outpatients in Anhui, China. PLoS One. 2015 Aug 14;10(8):e0135782.